You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMinocycline
Accession NumberDB01017  (APRD00547)
TypeSmall Molecule
GroupsApproved, Investigational
Description

A tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamideNot AvailableNot Available
7-Dimethylamino-6-demethyl-6-deoxytetracyclineNot AvailableNot Available
MinociclinaSpanishINN
MinociclinumNot AvailableNot Available
MinocyclinNot AvailableNot Available
MinocyclinumLatinINN
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ximinocapsule, extended release45 mgoralRanbaxy Laboratories Inc.2012-09-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Ximinocapsule, extended release90 mgoralRanbaxy Laboratories Inc.2012-09-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Ximinocapsule, extended release135 mgoralRanbaxy Laboratories Inc.2012-09-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocincapsule, coated pellets100 mgoralTriax Pharmaceuticals, LLC2007-09-012015-08-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocincapsule, coated pellets50 mgoralTriax Pharmaceuticals, LLC2007-09-012015-08-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocincapsule50 mgoralOnset Dermatologics, LLC2013-05-072015-08-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocincapsule, coated pellets50 mgoralOnset Dermatologics LLC1990-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
MinocinkitOnset Dermatologics, LLC2013-06-172016-01-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocincapsule100 mgoralOnset Dermatologics, LLC2013-05-072015-08-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocincapsule, coated pellets100 mgoralOnset Dermatologics LLC1990-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
MinocinkitOnset Dermatologics, LLC2013-06-172016-01-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocincapsule, coated pellets75 mgoralOnset Dermatologics LLC1990-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocininjection100 mgintravenousRempex Pharmaceuticals, Inc2013-04-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solodyntablet, film coated, extended release80 mgoralPhysicians Total Care, Inc.2011-07-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Arestinpowder1 mgoralOra Pharma, Inc.2011-03-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solodyntablet, film coated, extended release65 mgoralMedicis Pharmaceutical Corp.2009-07-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solodyntablet, film coated, extended release115 mgoralMedicis Pharmaceutical Corp.2009-07-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solodyntablet, film coated, extended release55 mgoralMedicis Pharmaceutical Corp.2010-09-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solodyntablet, film coated, extended release80 mgoralMedicis Pharmaceutical Corp.2010-09-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Solodyntablet, film coated, extended release105 mgoralMedicis Pharmaceutical Corp.2010-09-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Minocycline Hydrochloridecapsule50 mgoralTeva Pharmaceuticals USA Inc1992-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralTeva Pharmaceuticals USA Inc1992-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule75 mgoralTeva Pharmaceuticals USA Inc2004-06-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, extended release45 mgoralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-02-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, extended release90 mgoralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-02-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, extended release135 mgoralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-02-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.1999-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.1999-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule75 mgoralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.1999-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralKAISER FOUNDATION HOSPITALS2006-08-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralLiberty Pharmaceuticals, Inc.2000-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule75 mgoralActavis Pharma, Inc.1999-06-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralActavis Pharma, Inc.1991-12-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralActavis Pharma, Inc.1991-12-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, extended release45 mgoralSandoz Inc2009-08-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, extended release90 mgoralSandoz Inc2009-08-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, extended release135 mgoralSandoz Inc2009-08-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralRebel Distributors Corp.2000-11-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralAidarex Pharmaceuticals LLC2000-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralAidarex Pharmaceuticals LLC2000-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralAv Kare, Inc.2011-07-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralREMEDYREPACK INC.2011-03-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dynacintablet50 mgoralPar Pharmaceutical, Inc.2011-06-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dynacintablet75 mgoralPar Pharmaceutical, Inc.2011-06-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dynacintablet100 mgoralPar Pharmaceutical, Inc.2011-06-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocyclinetablet50 mgoralPar Pharmaceutical, Inc.2003-04-16Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocyclinetablet75 mgoralPar Pharmaceutical, Inc.2003-04-16Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocyclinetablet100 mgoralPar Pharmaceutical, Inc.2003-04-16Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralLake Erie Medical DBA Quality Care Products LLC1991-12-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralLake Erie Medical DBA Quality Care Products LLC2010-10-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralAv Pak2015-01-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralAv Pak2014-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralUnit Dose Services2008-03-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralUnit Dose Services2008-03-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralNorthwind Pharmaceuticals, LLC2014-08-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule75 mgoralREMEDYREPACK INC.2013-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralREMEDYREPACK INC.2013-07-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralPhysicians Total Care, Inc.2005-04-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralPhysicians Total Care, Inc.1993-09-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule75 mgoralPhysicians Total Care, Inc.2005-04-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, film coated50 mgoralDr. Reddy's Laboratories Limited2008-01-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, film coated75 mgoralDr. Reddy's Laboratories Limited2008-01-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, film coated100 mgoralDr. Reddy's Laboratories Limited2008-01-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralCardinal Health1991-12-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralCardinal Health1992-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralPd Rx Pharmaceuticals, Inc.1991-12-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralPd Rx Pharmaceuticals, Inc.1991-12-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralCaraco Pharmaceutical Laboratories, Ltd.2013-05-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule75 mgoralCaraco Pharmaceutical Laboratories, Ltd.2013-05-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralCaraco Pharmaceutical Laboratories, Ltd.2013-05-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralClinical Solutions Wholesale2008-03-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralDIRECT RX2014-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralDIRECT RX2014-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralProficient Rx LP2000-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralRanbaxy Pharmaceuticals Inc.2000-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule75 mgoralRanbaxy Pharmaceuticals Inc.2000-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralRanbaxy Pharmaceuticals Inc.2000-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, film coated50 mgoralRanbaxy Pharmaceuticals Inc.2004-06-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, film coated75 mgoralRanbaxy Pharmaceuticals Inc.2004-06-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, film coated100 mgoralRanbaxy Pharmaceuticals Inc.2004-06-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralbryant ranch prepack2000-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralbryant ranch prepack2000-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule75 mgoralbryant ranch prepack1999-06-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule50 mgoralAurobindo Pharma Limited2008-03-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule75 mgoralAurobindo Pharma Limited2008-03-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralAurobindo Pharma Limited2008-03-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, film coated, extended release45 mgoralAurobindo Pharma Limited2012-11-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, film coated, extended release90 mgoralAurobindo Pharma Limited2012-11-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, film coated, extended release135 mgoralAurobindo Pharma Limited2012-11-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralDispensing Solution, Inc.1991-12-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralAmerican Health Packaging2008-08-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralAmerican Health Packaging2012-09-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralCarilion Materials Management1991-12-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, extended release45 mgoralLupin Pharmaceuticals, Inc.2012-02-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, extended release90 mgoralLupin Pharmaceuticals, Inc.2012-02-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridetablet, extended release135 mgoralLupin Pharmaceuticals, Inc.2012-02-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocycline Hydrochloridecapsule100 mgoralPreferred Pharmaceuticals, Inc2000-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Minocyclinecapsule100 mgoralIvax Pharmaceuticals IncorporatedNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Minocyclinecapsule50 mgoralSanis Health IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Minocyclinecapsule100 mgoralSanis Health IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Over the Counter ProductsNot Available
International Brands
NameCompany
AkneminNot Available
Apo-MinocyclineNot Available
KlinomycinNot Available
MinodermNot Available
MinomycinNot Available
MinopenNot Available
MinoxNot Available
MinozNot Available
VectrinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Minocycline Hydrochloride
13614-98-7
Thumb
  • InChI Key: WTJXVDPDEQKTCV-VQAITOIOSA-N
  • Monoisotopic Mass: 493.161577972
  • Average Mass: 493.937
DBSALT000721
Categories
CAS number10118-90-8
WeightAverage: 457.4764
Monoisotopic: 457.184900233
Chemical FormulaC23H27N3O7
InChI KeyDYKFCLLONBREIL-KVUCHLLUSA-N
InChI
InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1
IUPAC Name
(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
SMILES
[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetracyclines. These are polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassTetracyclines
Sub ClassNot Available
Direct ParentTetracyclines
Alternative Parents
Substituents
  • Tetracycline
  • Tetracene
  • Naphthacene
  • Anthracene carboxylic acid or derivatives
  • Tetralin
  • Dialkylarylamine
  • Aryl ketone
  • Aralkylamine
  • Benzenoid
  • Vinylogous acid
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Primary carboxylic acid amide
  • Polyol
  • Ketone
  • Carboxamide group
  • Enol
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by Streptococcus pneumoniae and for the treatment of asymptomatic carriers of Neisseria meningitidis.
PharmacodynamicsMinocycline, the most lipid soluble and most active tetracycline antibiotic, is, like doxycycline, a long-acting tetracycline. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). Current research is examining the possible neuroprotective effects of minocycline against progression of Huntington's Disease, an inherited neurodegenerative disorder. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging.
Mechanism of actionMinocycline passes directly through the lipid bilayer or passively diffuses through porin channels in the bacterial membrane. Tetracyclines like minocycline bind to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.
AbsorptionRapidly absorbed from the gastrointestinal tract and absorption is not significantly impaired by ingestion of food or milk. Oral bioavailability is 100%.
Volume of distributionNot Available
Protein binding55% to 76%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life11-22 hours
ClearanceNot Available
ToxicityMinocycline has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs and monkeys). In the rat, chronic treatment with minocycline has resulted in goiter accompanied by elevated radioactive iodine uptake and evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. LD50=2380 mg/kg (rat, oral), LD50=3600 mg/kg (mouse, oral)
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategorySMPDB ID
Minocycline Action PathwayDrug actionSMP00292
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7469
Blood Brain Barrier-0.9783
Caco-2 permeable+0.5711
P-glycoprotein substrateSubstrate0.7366
P-glycoprotein inhibitor INon-inhibitor0.7968
P-glycoprotein inhibitor IINon-inhibitor0.7036
Renal organic cation transporterNon-inhibitor0.9536
CYP450 2C9 substrateNon-substrate0.8145
CYP450 2D6 substrateNon-substrate0.9036
CYP450 3A4 substrateSubstrate0.6805
CYP450 1A2 substrateNon-inhibitor0.9088
CYP450 2C9 substrateNon-inhibitor0.9071
CYP450 2D6 substrateNon-inhibitor0.9232
CYP450 2C19 substrateNon-inhibitor0.9081
CYP450 3A4 substrateNon-inhibitor0.9058
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7561
Ames testNon AMES toxic0.8909
CarcinogenicityNon-carcinogens0.9091
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4354 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9954
hERG inhibition (predictor II)Non-inhibitor0.6783
Pharmacoeconomics
Manufacturers
  • Medicis pharmaceutical corp
  • Triax pharmaceuticals llc
  • Aurobindo pharma ltd
  • Impax laboratories inc
  • Ranbaxy laboratories ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Lederle laboratories div american cyanamid co
  • Orapharma inc
  • Barr laboratories inc
  • Matrix laboratories ltd
  • Sandoz inc
  • Dr reddys laboratories ltd
  • Medicis Pharmaceutical Corporation
Packagers
Dosage forms
FormRouteStrength
Capsuleoral100 mg
Capsuleoral50 mg
Capsuleoral75 mg
Capsule, coated pelletsoral100 mg
Capsule, coated pelletsoral50 mg
Capsule, coated pelletsoral75 mg
Capsule, extended releaseoral135 mg
Capsule, extended releaseoral45 mg
Capsule, extended releaseoral90 mg
Injectionintravenous100 mg
Kit
Powderoral1 mg
Tabletoral100 mg
Tabletoral50 mg
Tabletoral75 mg
Tablet, extended releaseoral135 mg
Tablet, extended releaseoral45 mg
Tablet, extended releaseoral90 mg
Tablet, film coatedoral100 mg
Tablet, film coatedoral50 mg
Tablet, film coatedoral75 mg
Tablet, film coated, extended releaseoral105 mg
Tablet, film coated, extended releaseoral115 mg
Tablet, film coated, extended releaseoral135 mg
Tablet, film coated, extended releaseoral45 mg
Tablet, film coated, extended releaseoral55 mg
Tablet, film coated, extended releaseoral65 mg
Tablet, film coated, extended releaseoral80 mg
Tablet, film coated, extended releaseoral90 mg
Prices
Unit descriptionCostUnit
Minocin PAC 100 mg Kit Box695.5USD box
Minocin kit 100 mg combo668.17USD kit
Minocin kit 50 mg combo334.78USD kit
Minocin 100 mg vial59.64USD vial
Arestin 1 mg microsphere30.0USD each
Solodyn 135 mg 24 Hour tablet24.89USD tablet
Solodyn 45 mg 24 Hour tablet24.89USD tablet
Solodyn 65 mg 24 Hour tablet24.89USD tablet
Solodyn 90 mg 24 Hour tablet24.89USD tablet
Solodyn er 115 mg tablet23.93USD tablet
Solodyn er 135 mg tablet23.93USD tablet
Solodyn er 45 mg tablet23.93USD tablet
Solodyn er 65 mg tablet23.93USD tablet
Solodyn er 90 mg tablet23.93USD tablet
Minocycline hcl powder21.0USD g
Minocycline HCl 135 mg 24 Hour tablet19.21USD tablet
Minocycline HCl 45 mg 24 Hour tablet19.21USD tablet
Dynacin 100 mg tablet13.37USD tablet
Dynacin 75 mg tablet13.12USD tablet
Minocin 100 mg capsule12.05USD capsule
Minocin 100 mg pelletized cap11.11USD pellet
Dynacin 50 mg tablet8.76USD tablet
Dynacin 75 mg capsule7.15USD capsule
Minocycline hcl 100 mg tablet6.15USD tablet
Minocin 50 mg pelletized cap5.56USD pellet
Minocin 50 mg capsule5.24USD capsule
Minocycline hcl 75 mg tablet5.14USD tablet
Dynacin 50 mg capsule3.85USD capsule
Minocycline HCl 100 mg capsule3.53USD capsule
Minocycline hcl 50 mg tablet3.5USD tablet
Minocycline HCl 75 mg capsule2.06USD capsule
Minocycline 75 mg capsule1.98USD capsule
Minocycline HCl 50 mg capsule1.77USD capsule
Minocin 100 mg Capsule1.34USD capsule
Apo-Minocycline 100 mg Capsule1.08USD capsule
Minocycline 100 mg Capsule1.08USD capsule
Mylan-Minocycline 100 mg Capsule1.08USD capsule
Novo-Minocycline 100 mg Capsule1.08USD capsule
Pms-Minocycline 100 mg Capsule1.08USD capsule
Ratio-Minocycline 100 mg Capsule1.08USD capsule
Sandoz Minocycline 100 mg Capsule1.08USD capsule
Minocin 50 mg Capsule0.69USD capsule
Apo-Minocycline 50 mg Capsule0.56USD capsule
Minocycline 50 mg Capsule0.56USD capsule
Mylan-Minocycline 50 mg Capsule0.56USD capsule
Novo-Minocycline 50 mg Capsule0.56USD capsule
Pms-Minocycline 50 mg Capsule0.56USD capsule
Ratio-Minocycline 50 mg Capsule0.56USD capsule
Sandoz Minocycline 50 mg Capsule0.56USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada13305331994-07-052011-07-05
United States59088381998-02-192018-02-19
United States75413472007-04-022027-04-02
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility5.2E+004 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.05SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility3.07 mg/mLALOGPS
logP-0.03ALOGPS
logP-3.3ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)-2.3ChemAxon
pKa (Strongest Basic)8.25ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area164.63 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity122.54 m3·mol-1ChemAxon
Polarizability45.9 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Zita Mendes, Jose Rafael Antunes, Susana Marto, William Heggie, “Crystalline Minocycline Base and Processes for its Preparation.” U.S. Patent US20100286417, issued November 11, 2010.

US20100286417
General Reference
  1. Link
  2. Link
  3. Gough A, Chapman S, Wagstaff K, Emery P, Elias E: Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996 Jan 20;312(7024):169-72. Pubmed
  4. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801. Pubmed
  5. Tikka TM, Koistinaho JE: Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol. 2001 Jun 15;166(12):7527-33. Pubmed
  6. Nirmalananthan N, Greensmith L: Amyotrophic lateral sclerosis: recent advances and future therapies. Curr Opin Neurol. 2005 Dec;18(6):712-9. Pubmed
  7. Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z: Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport. 2004 Oct 5;15(14):2181-4. Pubmed
External Links
ATC CodesA01AB23J01AA08
AHFS Codes
  • 08:12.24
PDB Entries
FDA labelDownload (3.02 MB)
MSDSDownload (73.6 KB)
Interactions
Drug Interactions
Drug
Aluminum hydroxideMay decrease the absorption of Tetracycline Derivatives.
AmdinocillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
AmoxicillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
AmpicillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
AtazanavirMinocycline may decrease the serum concentration of Atazanavir.
AzidocillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
AzlocillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
BacampicillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
BenzylpenicillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
Bismuth SubsalicylateMay decrease the serum concentration of Tetracycline Derivatives.
Calcium carbonateMay decrease the absorption of Tetracycline Derivatives.
CarbenicillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
CloxacillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
ColesevelamMay decrease the absorption of Tetracycline Derivatives.
CyclacillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
DicloxacillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
FlucloxacillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
HetacillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
Magnesium oxideMay decrease the absorption of Tetracycline Derivatives.
MeticillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
MezlocillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
MipomersenTetracycline Derivatives may enhance the hepatotoxic effect of Mipomersen.
NafcillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
OxacillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
Penicillin VTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
PiperacillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
PivampicillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
PivmecillinamTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
PorfimerPhotosensitizing Agents may enhance the photosensitizing effect of Porfimer.
QuinaprilMay decrease the serum concentration of Tetracycline Derivatives.
SucralfateMay decrease the absorption of Tetracycline Derivatives.
TicarcillinTetracycline Derivatives may diminish the therapeutic effect of Penicillins.
VerteporfinPhotosensitizing Agents may enhance the photosensitizing effect of Verteporfin.
Food Interactions
  • Calcium and iron needs increased with long term use.
  • Do not take Aluminum or magnesium antacids or supplements while on this medication.
  • Take with food.

Targets

1. 30S ribosomal protein S9

Kind: protein

Organism: Escherichia coli (strain K12)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
30S ribosomal protein S9 P0A7X3 Details

References:

  1. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ: The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88. Pubmed

2. 30S ribosomal protein S4

Kind: protein

Organism: Escherichia coli (strain K12)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
30S ribosomal protein S4 P0A7V8 Details

References:

  1. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ: The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88. Pubmed

3. 16S rRNA

Kind: nucleotide

Organism: Enteric bacteria and other eubacteria

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

4. Interleukin-1 beta

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: modulator

Components

Name UniProt ID Details
Interleukin-1 beta P01584 Details

References:

  1. Sadowski T, Steinmeyer J: Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes. J Rheumatol. 2001 Feb;28(2):336-40. Pubmed
  2. Oringer RJ, Al-Shammari KF, Aldredge WA, Iacono VJ, Eber RM, Wang HL, Berwald B, Nejat R, Giannobile WV: Effect of locally delivered minocycline microspheres on markers of bone resorption. J Periodontol. 2002 Aug;73(8):835-42. Pubmed
  3. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB: A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14014-9. Pubmed
  4. Steinmeyer J, Daufeldt S, Taiwo YO: Pharmacological effect of tetracyclines on proteoglycanases from interleukin-1-treated articular cartilage. Biochem Pharmacol. 1998 Jan 1;55(1):93-100. Pubmed

5. Arachidonate 5-lipoxygenase

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Arachidonate 5-lipoxygenase P09917 Details

References:

  1. Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z: Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport. 2004 Oct 5;15(14):2181-4. Pubmed
  2. Song Y, Wei EQ, Zhang WP, Ge QF, Liu JR, Wang ML, Huang XJ, Hu X, Chen Z: Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation. Brain Res. 2006 Apr 26;1085(1):57-67. Epub 2006 Mar 30. Pubmed
  3. Chu LS, Fang SH, Zhou Y, Yu GL, Wang ML, Zhang WP, Wei EQ: Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats. Acta Pharmacol Sin. 2007 Jun;28(6):763-72. Pubmed

6. Matrix metalloproteinase-9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Matrix metalloproteinase-9 P14780 Details

References:

  1. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW: Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain. 2002 Jun;125(Pt 6):1297-308. Pubmed
  2. Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC: Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol. 2005 Jan;288(1):F91-7. Epub 2004 Sep 7. Pubmed
  3. Koistinaho M, Malm TM, Kettunen MI, Goldsteins G, Starckx S, Kauppinen RA, Opdenakker G, Koistinaho J: Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab. 2005 Apr;25(4):460-7. Pubmed
  4. Lee CZ, Yao JS, Huang Y, Zhai W, Liu W, Guglielmo BJ, Lin E, Yang GY, Young WL: Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab. 2006 Sep;26(9):1157-64. Epub 2006 Jan 4. Pubmed
  5. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC: Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 2006 Jul 17;7:56. Pubmed

7. Vascular endothelial growth factor A

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Vascular endothelial growth factor A P15692 Details

References:

  1. Sasamura H, Takahashi A, Miyao N, Yanase M, Masumori N, Kitamura H, Itoh N, Tsukamoto T: Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer. 2002 Mar 4;86(5):768-73. Pubmed
  2. Yao JS, Chen Y, Zhai W, Xu K, Young WL, Yang GY: Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res. 2004 Aug 20;95(4):364-71. Epub 2004 Jul 15. Pubmed
  3. Rocchetti R, Talevi S, Margiotta C, Calza R, Corallini A, Possati L: Antiangiogenic drugs for chemotherapy of bladder tumours. Chemotherapy. 2005 Oct;51(6):291-9. Epub 2005 Oct 13. Pubmed

8. Caspase-1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: negative modulator

Components

Name UniProt ID Details
Caspase-1 P29466 Details

References:

  1. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801. Pubmed
  2. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM: Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery. 2001 Jun;48(6):1393-9; discussion 1399-401. Pubmed
  3. Vincent JA, Mohr S: Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes. 2007 Jan;56(1):224-30. Pubmed
  4. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. Epub 2008 Oct 11. Pubmed

9. Caspase-3

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: negative modulator

Components

Name UniProt ID Details
Caspase-3 P42574 Details

References:

  1. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801. Pubmed
  2. Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM: Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol. 2002 Jul;52(1):54-61. Pubmed
  3. Dommergues MA, Plaisant F, Verney C, Gressens P: Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection. Neuroscience. 2003;121(3):619-28. Pubmed
  4. Lee SM, Yune TY, Kim SJ, Park DW, Lee YK, Kim YC, Oh YJ, Markelonis GJ, Oh TH: Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma. 2003 Oct;20(10):1017-27. Pubmed
  5. Baptiste DC, Hartwick AT, Jollimore CA, Baldridge WH, Seigel GM, Kelly ME: An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. Mol Pharmacol. 2004 Nov;66(5):1113-22. Epub 2004 Aug 10. Pubmed
  6. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. Epub 2008 Oct 11. Pubmed

10. Cytochrome c

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: negative modulator

Components

Name UniProt ID Details
Cytochrome c P99999 Details

References:

  1. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002 May 2;417(6884):74-8. Pubmed
  2. Matsuki S, Iuchi Y, Ikeda Y, Sasagawa I, Tomita Y, Fujii J: Suppression of cytochrome c release and apoptosis in testes with heat stress by minocycline. Biochem Biophys Res Commun. 2003 Dec 19;312(3):843-9. Pubmed
  3. Chu HC, Lin YL, Sytwu HK, Lin SH, Liao CL, Chao YC: Effects of minocycline on Fas-mediated fulminant hepatitis in mice. Br J Pharmacol. 2005 Jan;144(2):275-82. Pubmed
  4. Heo K, Cho YJ, Cho KJ, Kim HW, Kim HJ, Shin HY, Lee BI, Kim GW: Minocycline inhibits caspase-dependent and -independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice. Neurosci Lett. 2006 May 8;398(3):195-200. Epub 2006 Feb 15. Pubmed
  5. Mansson R, Hansson MJ, Morota S, Uchino H, Ekdahl CT, Elmer E: Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline. Neurobiol Dis. 2007 Jan;25(1):198-205. Epub 2006 Oct 24. Pubmed
  6. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. Epub 2008 Oct 11. Pubmed

Transporters

1. Solute carrier family 22 member 6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 6 Q4U2R8 Details

References:

  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. Pubmed

2. Solute carrier family 22 member 8

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 8 Q8TCC7 Details

References:

  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. Pubmed

3. Solute carrier family 22 member 11

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 11 Q9NSA0 Details

References:

  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. Pubmed

4. Solute carrier family 22 member 7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 7 Q9Y694 Details

References:

  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:13